Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Trials ...
PDS01ADC is a tumor-targeted IL-12 immunocytokine designed to activate the immune system directly within the tumor ...
These advances, still under investigation, hold the promise of revolutionizing healthcare for future colorectal cancer ...
Stocktwits on MSN
PDSB stock hits 37-week high — here’s the latest on its therapy to treat metastatic colorectal cancer
The trial focused on patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases ・The treatment delivered an ORR of nearly 78%, compared to 35% ...
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San ...
NEXT-GENERATION sequencing use rose in advanced cancer, but access remained uneven across socioeconomic, racial, and ...
Craig Heffentrager was treated at the interventional radiology suite at Jefferson Torresdale Hospital, where he was treated ...
New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results